Background

Type II transmembrane serine proteases (TTSPs) have been identified as potential therapeutic targets for the treatment of respiratory infections by coronaviruses, MERS and influenza. These enzymes are involved in a key component of viral infection (viral spike protein processing) which enable the virus to enter the host cells.

Researchers have developed ketobenzothiazole containing peptidomimetic protease inhibitors in a previous influenza program. So far, preclinical data demonstrate potent antiviral activity against SARS-CoV-2 infection in vitro as well as in vivo in a prophylactic paradigm.

This host-based, broad range respiratory antiviral class of compound is well positioned as a key preparedness step for potential future pandemics requiring immediate intervention when vaccines are not readily available.